Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

Cancer

Volumn 89, Issue 2, 2000, Pages 431-436

  Trivedi, Charu ^a   Redman, Bruce ^b   Flaherty, Lawrence E ^a   Kucuk, Omer ^a   Du, Wei ^a   Heilbrun, Lance K ^a   Hussain, Maha ^a,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Androgen independent status; Dose limiting toxicity; Hormone refractory prostate carcinoma; Weekly paclitaxel

Indexed keywords

ANTIANDROGEN; DEXAMETHASONE; GONADORELIN AGONIST; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG INTERMITTENT THERAPY; EDEMA; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPH NODE METASTASIS; MALE; MUSCLE DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME;

AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0034662046     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B     Document Type: Article

References (40)